Cancer Research Cell Death Mechanisms and Cancer Therapy  Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Boo, L. M.
Right arrow Articles by Ann, D. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Boo, L. M.
Right arrow Articles by Ann, D. K.
[Cancer Research 65, 6622-6630, August 1, 2005]
© 2005 American Association for Cancer Research


Molecular Biology, Pathobiology and Genetics

High Mobility Group A2 Potentiates Genotoxic Stress in Part through the Modulation of Basal and DNA Damage–Dependent Phosphatidylinositol 3-Kinase–Related Protein Kinase Activation

Lee Ming Boo1, H. Helen Lin1, Vincent Chung5, Bingsen Zhou5, Stan G. Louie3, Michael A. O'Reilly6, Yun Yen1,5 and David K. Ann1,2,4

Departments of 1 Molecular Pharmacology and Toxicology, 2 Medicine, and 3 Pharmacy, and 4 Norris Cancer Center, University of Southern California, Los Angeles, California; 5 Department of Medical Oncology and Therapeutic Research, City of Hope National Medical Center, Duarte, California; and 6 Department of Pediatrics, University of Rochester, Rochester, New York

Requests for reprints: David K. Ann, University of Southern California, Health Science Campus, PSC-209, 1985 Zonal Avenue, Los Angeles, CA 90033-1049. Phone: 323-442-3409; Fax: 323-224-7473; E-mail: ann{at}usc.edu.

The high mobility group A2 (HMGA2) protein belongs to the architectural transcription factor HMGA family, playing a role in chromosomal organization and transcriptional regulation. We and others have previously reported that ectopic HMGA2 expression is associated with neoplastic transformation and anchorage-independent cell proliferation. Here, we reported a correlation between increased HMGA2 expression and enhanced chemosensitivity towards topoisomerase II inhibitor, doxorubicin, in breast cancer cells. Using cells exhibiting differential HMGA2 expression and small interfering RNA technique, we showed that HMGA2 expression modulates cellular response to the genotoxicity of DNA double-strand breaks. Notably, HMGA2 enhances doxorubicin-elicited cell cycle delay in sub-G1 and G2-M and augments cell cycle dysregulation on cotreatment of doxorubicin and caffeine. We further reported that HMGA2 induces a persistent Ser139 phosphorylation of histone 2A variant X, analogous to the activation by doxorubicin-mediated genotoxic stress. Moreover, this HMGA2-dependent enhancement of cytotoxicity is further extended to other double-strand breaks elicited by cisplatin and X-ray irradiation and is not restricted to one cell type. Together, we postulated that the enhanced cytotoxicity by double-strand breaks in HMGA2-expressing cells is mediated, at least in part, through the signaling pathway of which the physiologic function is to maintain genome integrity. These findings should contribute to a greater understanding of the role of HMGA2 in promoting tumorigenesis and conveying (chemo)sensitivity towards doxorubicin and other related double-strand breaks.




This article has been cited by other articles:


Home page
Mol Cancer ResHome page
L. Du, J. J. Schageman, M. C. Subauste, B. Saber, S. M. Hammond, L. Prudkin, I. I. Wistuba, L. Ji, J. A. Roth, J. D. Minna, et al.
miR-93, miR-98, and miR-197 Regulate Expression of Tumor Suppressor Gene FUS1
Mol. Cancer Res., August 1, 2009; 7(8): 1234 - 1243.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. Y.J. Li, L. M. Boo, S.-Y. Wang, H. H. Lin, C. C.C. Wang, Y. Yen, B. P.C. Chen, D. J. Chen, and D. K. Ann
Suppression of Nonhomologous End Joining Repair by Overexpression of HMGA2
Cancer Res., July 15, 2009; 69(14): 5699 - 5706.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
H. Summer, O. Li, Q. Bao, L. Zhan, S. Peter, P. Sathiyanathan, D. Henderson, T. Klonisch, S. D. Goodman, and P. Droge
HMGA2 exhibits dRP/AP site cleavage activity and protects cancer cells from DNA-damage-induced cytotoxicity during chemotherapy
Nucleic Acids Res., July 1, 2009; 37(13): 4371 - 4384.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
X. Cao, C. Clavijo, X. Li, H. H. Lin, Y. Chen, H.-M. Shih, and D. K. Ann
SUMOylation of HMGA2: selective destabilization of promyelocytic leukemia protein via proteasome
Mol. Cancer Ther., April 1, 2008; 7(4): 923 - 934.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. E. Adair, S. C. Maloney, G. A. Dement, K. J. Wertzler, M. J. Smerdon, and R. Reeves
High-Mobility Group A1 Proteins Inhibit Expression of Nucleotide Excision Repair Factor Xeroderma Pigmentosum Group A
Cancer Res., July 1, 2007; 67(13): 6044 - 6052.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2005 by the American Association for Cancer Research.